More recently, the randomized study with the anti-EGFR antibody nimotuzumab plus gemcitabine vs. gemcitabine alone in KRASWT PDA (n = 90) showed OS benefit (10.9 vs. 8.5 months, HR = 0.62; p = 0.04) [12]. The gene discussed is EGFR; the disease is Patent ductus arteriosus.